Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xingya Li

Showing results (91-100 of 146) with videos related to

Pageof 15
Sort By:
British Journal of Cancer|December 19, 2023
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancerBolin Chen, Wenxiu Yao, Xingya Li, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 24, 2025
Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical StudiesYan Sun, Haochen Yang, Qing Xu, et al.
JAMA Oncology|June 4, 2026
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical TrialJingjing Liu, Liang Han, Lin Wu, et al.
JAMA|September 27, 2022
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical TrialYing Cheng, Liang Han, Lin Wu, et al.
The Lancet. Respiratory Medicine|May 8, 2023
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trialShun Lu, Lin Wu, Hong Jian, et al.
The Lancet. Oncology|July 31, 2022
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trialShun Lu, Lin Wu, Hong Jian, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2024
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I studyQing Zhou, Nong Yang, Mingfang Zhao, et al.
The Lancet. Oncology|February 28, 2025
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm studyZiming Li, Yan Wang, Yuping Sun, et al.
The Lancet. Oncology|September 23, 2020
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Zhiwei Zhou, et al.
The Lancet. Oncology|May 16, 2022
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialJie Wang, Caicun Zhou, Wenxiu Yao, et al.
Pageof 15

Showing results (91-100 of 146) with videos related to

Sort By:
Pageof 15
British Journal of Cancer|December 19, 2023
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancerBolin Chen, Wenxiu Yao, Xingya Li, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 24, 2025
Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical StudiesYan Sun, Haochen Yang, Qing Xu, et al.
JAMA Oncology|June 4, 2026
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical TrialJingjing Liu, Liang Han, Lin Wu, et al.
JAMA|September 27, 2022
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical TrialYing Cheng, Liang Han, Lin Wu, et al.
The Lancet. Respiratory Medicine|May 8, 2023
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trialShun Lu, Lin Wu, Hong Jian, et al.
The Lancet. Oncology|July 31, 2022
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trialShun Lu, Lin Wu, Hong Jian, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2024
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I studyQing Zhou, Nong Yang, Mingfang Zhao, et al.
The Lancet. Oncology|February 28, 2025
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm studyZiming Li, Yan Wang, Yuping Sun, et al.
The Lancet. Oncology|September 23, 2020
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Zhiwei Zhou, et al.
The Lancet. Oncology|May 16, 2022
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialJie Wang, Caicun Zhou, Wenxiu Yao, et al.
Pageof 15